Q1problem
[25 marks]MegaCorp, a large German pharmaceutical company, has been fined €50 million by the European Commission for allegedly restricting parallel imports of its patented medicines across EU Member States. MegaCorp argues that its actions were justified to protect intellectual property rights and maintain quality control. The company also claims that the Commission's investigation violated the principle of proportionality by imposing excessive penalties without considering less restrictive alternatives. Additionally, MegaCorp contends that certain procedural rights were breached during the investigation process. Advise MegaCorp on the likelihood of success in challenging the Commission's decision before the Court of Justice of the European Union, focusing particularly on EU principles.